Radiotherapy for localized prostate carcinoma: The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen

Cancer

Volumn 79, Issue 2, 1997, Pages 328-336

  Crook, Juanita M ^a,c   Bahadur, Yasir A ^a   Bociek, R Gregory ^a   Perry, Gad A ^a   Robertson, Susan J ^b   Esche, Bernd A ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c Department of Radiation Oncology ^*  (Canada)

Author keywords

nadir PSA; pretreatment PSA; prostate carcinoma; radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CARCINOMA; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT FAILURE;

AGED; AGED, 80 AND OVER; BIOPSY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 0031024370     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970115)79:2<328::AID-CNCR16>3.0.CO;2-2     Document Type: Article

References (24)

1. Kuban DA, El-Mahdi AM, Schellhammer PF. Prostate specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:307-16.
2. Lee WR, Hanks GE, Schultheiss TE, Corn BW, Hunt MA. Localized prostate cancer treated by external beam radiotherapy alone: serum prostate specific antigen outcome driven analysis. J Clin Oncol 1995; 13:464-9.
3. Russell KJ, Boileau MA. Current status of prostate specific antigen in the management of prostatic cancer. Semin Radiat Oncol 1993;3:154-68.
4. Zagars GK, Pollack A. Radiation therapy for Tl and T2 prostate cancer: prostate-specific antigen and disease outcome. Urology 1995;45:476-83.
5. Zietman A, Coen J, Shipley W, Willett CG, Efrid JT. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994; 151:640-5.
6. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy: the Johns Hopkins experience after 10 years. Urol Clin North Am 1993;20:713-25.
7. Stamey TA, Graves HCB, Wehner N, Ferrari M, Freiha F. Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen. J Urol 1993; 149:787-92.
8. Mostofi FK, Sesterhenn IA, Davis CJ, Jr. A pathologist's view of prostatic carcinoma. Cancer 1993;71(suppl):906-32,
9. Blasko J, Ragde H, Grimm P, Cavanagh W, Kenny G. Transperineal ultrasound guided palladium-103 brachytherapy for prostate carcinoma. J Urol 1995; 153:385A.
10. Kuban DA, El-Mahdi AM, Schellhammer PF. Potential benefit of improved local tumor control in patients with prostate carcinoma. Cancer 1995;75:2373-82.
11. Crook JM, Perry GA, Robertson S, Esche BA. Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology 1995;45:625-32.
12. Hermanek P, Sobin LH, editors. International Union Against Cancer. TNM classification of malignant tumors. 4th edition, 2nd revision. Berlin: Springer-Verlag, 1992.
13. Brawer MK, Nagle RB, Pitts W, Freiha F, Gamble SL. Keratin immunoreactivity as an aid to the diagnosis of persistent adenocarcinoma in irradiated human prostates. Cancer 1989;63:454-60.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
15. Pisansky TM, Cha SS, Earle JD, Durr D, Kozelsky TF, Wieand HS, et al. Prostate specific antigen as a pretherapy prognostic factor for patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 1993; 11:2158-66.
16. Mantel N. Evaluation of survival and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
17. Cox DR. Regression models and life tables. J R Stat Soc [B] 1972;34:187-220.
18. Willet CG, Zietman AL, Shipley WU, et al. The effect of pelvic radiation therapy on serum levels of prostate specific antigen. J Urol 1994; 151:1579-81.
19. Hanks GE, Corn BW, Lee WR, Hunt M, Hanton A, Schultheiss TE. External beam irradiation of prostate cancer. Cancer 1995;75(suppl):1972-7.
20. Zagars GK, von Eschenbach AC. Prostate specific antigen: an important marker for prostate cancer treated by external beam radiation therapy. Cancer 1993;72:538-48.
21. Zagars GK, Pollack A, Kavadi VS, von Eschenbach AC. Prostate specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:293-306.
22. Zagars GK. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J Urol 1994;152:1786-91.
23. Kuban DA, El-Mahdi AM. Local control after irradiation for prostatic carcinoma: significance and assessment. Semin Radiat Oncol 1993;3:221-9.
24. Zagars GK, Pollack AP, von Eschenbach AC. Prostate cancer and radiation therapy: the message conveyed by serum prostate specific antigen. Int J Radiat Oncol Biol Phys 1995;33:23-35.